Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00582166 · ClinicalTrials.gov registry record · Phase 2
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00582166 is a Phase 2 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 18 participants.
The verdict
NCT00582166, a Phase 2 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
Interventions
- DRUG Ibritumomab Tiuxetan (Zevalin) + Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2005-01-25 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00582166
The ClinicalTrials.gov registry entry for NCT00582166 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ibritumomab Tiuxetan (Zevalin) + Rituximab is the first listed.
NCT00582166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00582166 about?
NCT00582166 is a clinical study titled "Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance". Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
What is the current status of trial NCT00582166?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2005-01-25. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00582166?
The interventions under investigation include: Ibritumomab Tiuxetan (Zevalin) + Rituximab (DRUG).
Who is sponsoring clinical trial NCT00582166?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.